Acute kidney injury in patients with SARS-CoV-2 infection

被引:59
作者
Joseph, Adrien [1 ]
Zafrani, Lara [1 ,3 ]
Mabrouki, Asma [1 ]
Azoulay, Elie [1 ,2 ]
Darmon, Michael [1 ,2 ]
机构
[1] Paris Univ, Hop St Louis, AP HP, Serv Med Intens & Reanimat Med, 1 Ave Claude Vellefaux, F-75010 Paris, France
[2] Univ Paris, INSERM, ECSTRA Team, UMR 1153,Ctr Epidemiol & Biostat, Paris, France
[3] Univ Paris, INSERM U976, Paris, France
关键词
Acute kidney injury; COVID-19; Complement system proteins; Interleukin-6; Outcome; Intensive care units; HOSPITALIZED-PATIENTS; COVID-19; WUHAN;
D O I
10.1186/s13613-020-00734-z
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background Acute Kidney Injury (AKI) is a frequent complication of severe SARS-CoV-2 infection. Multiple mechanisms are involved in COVID-19-associated AKI, from direct viral infection and secondary inflammation to complement activation and microthrombosis. However, data are limited in critically-ill patients. In this study, we sought to describe the prevalence, risk factors and prognostic impact of AKI in this setting. Methods Retrospective monocenter study including adult patients with laboratory confirmed SARS-CoV-2 infection admitted to the ICU of our university Hospital. AKI was defined according to both urinary output and creatinine KDIGO criteria. Results Overall, 100 COVID-19 patients were admitted. AKI occurred in 81 patients (81%), including 44, 10 and 27 patients with AKI stage 1, 2 and 3 respectively. The severity of AKI was associated with mortality at day 28 (p = 0.013). Before adjustment, the third fraction of complement (C3), interleukin-6 (IL-6) and ferritin levels were higher in AKI patients. After adjustment for confounders, both severity (modified SOFA score per point) and AKI were associated with outcome. When forced in the final model, C3 (OR per log 0.25; 95% CI 0.01-4.66), IL-6 (OR per log 0.83; 95% CI 0.51-1.34), or ferritin (OR per log 1.63; 95% CI 0.84-3.32) were not associated with AKI and did not change the model. Conclusion In conclusion, we did not find any association between complement activation or inflammatory markers and AKI. Proportion of patients with AKI during severe SARS-CoV-2 infection is higher than previously reported and associated with outcome.
引用
收藏
页数:8
相关论文
共 36 条
[1]  
[Anonymous], 2012, KIDNEY INT SUPPL, V2, P1, DOI DOI 10.1038/KISUP.2012.1
[2]  
[Anonymous], COVID 19 MAP
[3]   Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology [J].
Batlle, Daniel ;
Soler, Maria Jose ;
Sparks, Matthew A. ;
Hiremath, Swapnil ;
South, Andrew M. ;
Welling, Paul A. ;
Swaminathan, Sundararaman .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (07) :1380-1383
[4]   Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome [J].
Beloncle, Francois M. ;
Pavlovsky, Bertrand ;
Desprez, Christophe ;
Fage, Nicolas ;
Olivier, Pierre-Yves ;
Asfar, Pierre ;
Richard, Jean-Christophe ;
Mercat, Alain .
ANNALS OF INTENSIVE CARE, 2020, 10 (01)
[5]   Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit [J].
Cao, Jianlei ;
Hu, Xiaoyong ;
Cheng, Wenlin ;
Yu, Lei ;
Tu, Wen-Jun ;
Liu, Qiang .
INTENSIVE CARE MEDICINE, 2020, 46 (05) :851-853
[6]  
Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
[7]   COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? [J].
Colafrancesco, Serena ;
Alessandri, Cristiano ;
Conti, Fabrizio ;
Priori, Roberta .
AUTOIMMUNITY REVIEWS, 2020, 19 (07)
[8]  
Diao B, 2020, MEDRXIV, DOI [10.1101/2020.03.04.20031120, 10.1101]
[9]   Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 [J].
Ferrario, CM ;
Jessup, J ;
Chappell, MC ;
Averill, DB ;
Brosnihan, KB ;
Tallant, EA ;
Diz, DI ;
Gallagher, PE .
CIRCULATION, 2005, 111 (20) :2605-2610
[10]   Acute kidney injury in critically ill patients with COVID-19 [J].
Gabarre, Paul ;
Dumas, Guillaume ;
Dupont, Thibault ;
Darmon, Michael ;
Azoulay, Elie ;
Zafrani, Lara .
INTENSIVE CARE MEDICINE, 2020, 46 (07) :1339-1348